A Phase II, Randomized, Double-Blind, Parallel-Group Study to Evaluate the Efficacy and Safety of Ocrelizumab in Combination With Methotrexate Compared With Infliximab Plus Methotrexate in Patients With Active Rheumatoid Arthritis Currently Responding Inadequately to Etanercept or Adalimumab.

Trial Profile

A Phase II, Randomized, Double-Blind, Parallel-Group Study to Evaluate the Efficacy and Safety of Ocrelizumab in Combination With Methotrexate Compared With Infliximab Plus Methotrexate in Patients With Active Rheumatoid Arthritis Currently Responding Inadequately to Etanercept or Adalimumab.

Discontinued
Phase of Trial: Phase II

Latest Information Update: 08 Jul 2016

At a glance

  • Drugs Ocrelizumab (Primary) ; Infliximab; Methotrexate; Methotrexate; Methylprednisolone
  • Indications Rheumatoid arthritis
  • Focus Therapeutic Use
  • Acronyms CINEMA
  • Sponsors Genentech
  • Most Recent Events

    • 27 May 2010 Status changed from active, no longer recruiting to discontinued as reported by ClinicalTrials.gov.
    • 06 Apr 2010 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
    • 14 Jan 2010 Additional lead trial centres and investigators identified as reported by Oregon Health and Science University.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top